Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CND004
MIFTS: 63

Candidiasis

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases, Reproductive diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Candidiasis

About this section

MalaCards integrated aliases for Candidiasis:

Name: Candidiasis 12 77 56 3 45 15 74
Systemic Candidiasis 12 54 74
Invasive Candidiasis 54 3 74
Disseminated Candidiasis 12 56
Systemic Candida Infections 54
Candidiasis, Invasive 17

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases Genetic diseases
Anatomical: Blood diseases Neuronal diseases Reproductive diseases Oral diseases Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1508
ICD9CM 36 112 112.9
MeSH 45 D002177
NCIt 51 C26711
SNOMED-CT 69 78048006
ICD10 34 B37 B37.9
Sources

Summaries for Candidiasis

About this section
NIH Rare Diseases : 54 Systemic candidiasis includes a spectrum of yeast infections caused by different species (types) of Candida. It is a serious infection that can affect the blood, heart, brain, eyes, bones, or other parts of the body. Although there are over 200 species of Candida, five different species of Candida cause 90% of systemic candidiasis. The most common form of this invasive yeast infection is when Candida enters the bloodstream (candidemia). Signs of candidemia include fever and chills that do not improve with antibiotics. Symptoms of other types of systemic candidiasis depend on the organ or system which is infected. Systemic candidiasis is the most common fungal infection among hosptilized people in high-income countries, including the United States. Diagnosis can be difficult, especially when the Candida is not found in the bloodstream. Treatment usually includes consists of oral or intravenous (IV) antifungal medications. 

MalaCards based summary : Candidiasis, also known as systemic candidiasis, is related to candidiasis, familial, 2 and vulvovaginal candidiasis. An important gene associated with Candidiasis is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Miconazole and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and brain, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An opportunistic mycosis that involves fungal infection of the mouth, throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, heart and brain by Candida species, of which Candida albicans is the most common. Systemic Candida infections are usually confined to severely immunocompromised persons.

CDC : 3  

Wikipedia : 77 Candidiasis is a fungal infection due to any type of Candida (a type of yeast). When it affects the... more...

Sources

Related Diseases for Candidiasis

About this section

Diseases in the Candidiasis family:

Candidiasis, Familial, 1 Candidiasis, Familial, 2
Candidiasis, Familial, 3 Candidiasis, Familial, 4
Candidiasis, Familial, 6 Candidiasis, Familial, 8
Candidiasis, Familial, 9 Familial Candidiasis

Diseases related to Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 410)
# Related Disease Score Top Affiliating Genes
1 candidiasis, familial, 2 34.4 CARD9 CLEC7A
2 vulvovaginal candidiasis 34.4 CLEC7A DEFB4A MBL2
3 familial candidiasis 34.3 CARD9 IL17F IL17RA
4 oral candidiasis 34.0 DEFB4A HTN3 SKAP2
5 chronic mucocutaneous candidiasis 32.3 AIRE CARD9 CLEC7A IFNG IL10 IL17A
6 candida glabrata 31.4 APCS HTN3 IFNG SKAP2
7 cryptococcosis 30.8 CARD9 IFNG MBL2
8 bacterial vaginosis 30.7 DEFB4A IL1B MBL2
9 aspergillosis 30.7 CLEC7A IFNG IL10 MBL2
10 invasive aspergillosis 30.7 CLEC7A IFNG MBL2
11 acquired immunodeficiency syndrome 30.4 IFNG IL10 IL1B
12 meningitis 30.0 IFNG IL10 IL1B MBL2
13 sporotrichosis 30.0 IFNG IL10
14 hematopoietic stem cell transplantation 29.9 CLEC7A IFNG IL10
15 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.9 AIRE IFNG IL10
16 myasthenia gravis 29.9 AIRE IFNG IL10
17 trichosporonosis 29.8 IFNG IL17A
18 chlamydia 29.7 IFNG IL10 IL1B
19 lung disease 29.7 IL10 IL17A IL1B MBL2
20 arthritis 29.7 IFNG IL10 IL17A IL1B
21 uveitis 29.6 IFNG IL10 IL17A
22 lymphadenitis 29.5 IFNG IL10 IL1B
23 osteomyelitis 29.5 IFNG IL10 IL1B
24 neurosyphilis 29.5 IL10 IL17A
25 toxoplasmosis 29.5 IFNG IL10 IL1B
26 coccidioidomycosis 29.5 CARD9 CLEC7A IL10 MBL2 STAT1
27 vulvar vestibulitis syndrome 29.4 IL1B MBL2
28 autoimmune disease 29.4 AIRE IFNG IL10 IL17A IL1B
29 dermatitis, atopic 29.3 DEFB4A IFNG IL10 IL17A
30 systemic lupus erythematosus 29.3 IFNG IL10 IL17A IL1B MBL2 STAT1
31 multiple sclerosis 29.1 IFNG IL10 IL17A IL1B
32 inflammatory bowel disease 29.0 IFNG IL10 IL17A IL1B STAT1
33 bacterial infectious disease 29.0 DEFB4A IFNG IL10 IL17A IL1B MBL2
34 human immunodeficiency virus type 1 28.8 APCS HSP90AA1 HTN3 IFNG IL10 STAT1
35 candidiasis, familial, 6 12.6
36 neonatal candidiasis 12.5
37 candidiasis, familial, 8 12.5
38 candidiasis, familial, 4 12.5
39 esophageal candidiasis 12.5
40 cutaneous candidiasis 12.5
41 candidiasis, familial, 9 12.4
42 candidiasis, familial, 1 12.4
43 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 12.2
44 candidiasis, familial, 3 12.1
45 immunodeficiency 51 12.1
46 immunodeficiency 31c 12.1
47 autoimmune polyendocrine syndrome type 1 12.1
48 candidal paronychia 11.9
49 vaginitis 11.3
50 myeloperoxidase deficiency 11.3

Comorbidity relations with Candidiasis via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Intestinal Obstruction
Paralytic Ileus Protein-Energy Malnutrition
Respiratory Failure

Graphical network of the top 20 diseases related to Candidiasis:



Diseases related to Candidiasis
Sources

Symptoms & Phenotypes for Candidiasis

About this section

MGI Mouse Phenotypes related to Candidiasis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 AIRE APCS CARD9 CLEC7A IFNG IL10
2 immune system MP:0005387 10.16 AIRE APCS CARD9 CLEC7A HSP90AA1 IFNG
3 homeostasis/metabolism MP:0005376 10.13 AIRE APCS CARD9 CLEC7A IFNG IL10
4 digestive/alimentary MP:0005381 10.01 AIRE CLEC7A IFNG IL10 IL17A IL17F
5 craniofacial MP:0005382 9.98 HSP90AA1 IFNG IL10 IL17A IL17F IL1B
6 mortality/aging MP:0010768 9.93 AIRE APCS CLEC7A HSP90AA1 IFNG IL10
7 neoplasm MP:0002006 9.43 AIRE IFNG IL10 IL17RA IL1B STAT1
8 respiratory system MP:0005388 9.23 AIRE CLEC7A IFNG IL10 IL17A IL17F
Sources

Drugs & Therapeutics for Candidiasis

About this section

Drugs for Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
2
Fluconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 86386-73-4 3365
3
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 166663-25-8 166548
4
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23593-75-1 2812
5
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 18323-44-9 29029
6
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
7
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1397-89-3 5280965 14956
8
Micafungin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 235114-32-6 477468 3081921
9
Metronidazole Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 443-48-1 4173
10
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
11
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
12
Caspofungin Approved Phase 4,Phase 3,Phase 2,Not Applicable 162808-62-0, 179463-17-3 2826718 468682
13
Dequalinium Approved, Investigational Phase 4 6707-58-0
14
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
15
Terconazole Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 67915-31-5 441383
16
Racepinephrine Approved Phase 4 329-65-7 838
17
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
18
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1400-61-9 11953884
19
Zinc Approved, Investigational Phase 4 7440-66-6 32051
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Nevirapine Approved Phase 4 129618-40-2 4463
22
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
23
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
24
Sirolimus Approved, Investigational Phase 4,Phase 3 53123-88-9 46835353 5284616 6436030
25
Everolimus Approved Phase 4,Phase 3 159351-69-6 70789204 6442177
26
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6 774
27
Methotrexate Approved Phase 4,Phase 3 1959-05-2, 59-05-2 126941
28
Simethicone Approved Phase 4,Phase 3 8050-81-5
29
Aluminum hydroxide Approved, Investigational Phase 4,Phase 1,Phase 2 21645-51-2
30
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 171228-49-2 147912
31
Tinidazole Approved, Investigational Phase 4,Phase 3 19387-91-8 5479
32
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 84625-61-6 55283
33
Promethazine Approved, Investigational Phase 4 60-87-7 4927
34
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
35
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
36
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
37
Povidone Approved Phase 4 9003-39-8
38
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
39
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
40
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
41
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
42
Zidovudine Approved Phase 4 30516-87-1 35370
43
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
44
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
45
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4 8001-79-4
46 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Steroid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 367)
# Name Status NCT ID Phase Drugs
1 Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week Unknown status NCT00537888 Phase 4 fluconazole
2 A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in Intensive Care Unit (ICU) Patients Unknown status NCT01734525 Phase 4 Anidulafungin
3 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
4 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
5 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
6 An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis Completed NCT01769339 Phase 4 Miconazole plus Hydrocortisone
7 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) Completed NCT00520234 Phase 4 Caspofungin;Normal Saline
8 Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania Completed NCT00553137 Phase 4 fluconazole;fluconazole
9 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
10 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
11 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
12 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis Completed NCT00548262 Phase 4 Anidulafungin;Voriconazole
13 CRITIC - Treatment of Candidemia and Invasive Candidiasis Completed NCT00670657 Phase 4 AmBisome
14 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
15 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
16 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
17 Optimal Dosage of Caspofungin in Critically Ill Patients Completed NCT01994096 Phase 4 Caspofungin
18 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
19 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
20 Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants Completed NCT00001107 Phase 4 Fluconazole;AmBisome
21 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
22 Effectiveness of Hygiene Solutions on Denture Biofilm Completed NCT02407834 Phase 4
23 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
24 Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients Completed NCT01495039 Phase 4 Nystatin
25 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
26 Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT) Completed NCT02021123 Phase 4 Anidulafungin 100mg single dose iv
27 Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration Completed NCT02651038 Phase 4 Micafungin
28 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
29 Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants Completed NCT01531192 Phase 4 Nystatin
30 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
31 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
32 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins Completed NCT00839540 Phase 4 micafungin;Micafungin;Caspofungin
33 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
34 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
35 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
36 Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin Recruiting NCT03906916 Phase 4 Micafungin
37 Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
38 Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals Active, not recruiting NCT03723525 Phase 4
39 Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Not yet recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
40 Evaluation of Efficacy and Safety of Gynomax® XL Ovule Not yet recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
41 A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Terminated NCT01982071 Phase 4 Micafungin
42 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
43 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
44 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
45 Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients Withdrawn NCT00304772 Phase 4 Fluconazole;Micafungin
46 RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section Withdrawn NCT02009098 Phase 4 Cefuroxime
47 Fluconazole Versus Micafungin in Neonates With Candidiasis Unknown status NCT02145832 Phase 2, Phase 3 Fluconazole;Micafungin
48 Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
49 Dysbiosis in Localized Provoked Vulvodynia (LPV) Unknown status NCT02393911 Phase 3
50 Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia Unknown status NCT01270490 Phase 3 Interferon-gamma, Recombinant

Search NIH Clinical Center for Candidiasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: candidiasis

Sources

Genetic Tests for Candidiasis

About this section
Sources

Anatomical Context for Candidiasis

About this section

MalaCards organs/tissues related to Candidiasis:

42
Colon, Testes, Brain, Skin, T Cells, Heart, Bone
Sources

Publications for Candidiasis

About this section

Articles related to Candidiasis:

(show top 50) (show all 3851)
# Title Authors Year
1
Impact of Antimicrobial Prophylaxis for Severe Acute Pancreatitis on the Development of Invasive Candidiasis: A Large Retrospective Multicenter Cohort Study. ( 30946245 )
2019
2
Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis. ( 30284178 )
2019
3
Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients. ( 30658200 )
2019
4
Candidiasis associated with very early onset inflammatory bowel disease: First IL10RB deficient case from the National Iranian Registry and review of the literature. ( 31096038 )
2019
5
Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis. ( 31106557 )
2019
6
Probiotics for Oral and Vulvovaginal Candidiasis: A Review. ( 31112355 )
2019
7
Alternative and complementary therapies for vulvovaginal candidiasis. ( 30269301 )
2019
8
Genotyping of Candida albicans and Candida dubliniensis by 25S rDNA analysis shows association with virulence attributes in oral candidiasis. ( 30321765 )
2019
9
Prospective evaluation of lymphocyte subtyping for the diagnosis of invasive candidiasis in non-neutropenic critically ill patients. ( 30399447 )
2019
10
A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age. ( 30418357 )
2019
11
Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. ( 30184181 )
2019
12
The Frequency and Risk Factors for Oropharyngeal Candidiasis in Adult Asthma Patients Using Inhaled Corticosteroids. ( 30958987 )
2019
13
T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study-authors' response. ( 30476190 )
2019
14
Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. ( 30565240 )
2019
15
Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. ( 30595144 )
2019
16
Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis. ( 30621597 )
2019
17
Immunologic characterization of patients with chronic mucocutaneous candidiasis disease. ( 30656037 )
2019
18
Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. ( 30656691 )
2019
19
Author Correction: Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. ( 30659194 )
2019
20
Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial. ( 30663184 )
2019
21
Antifungal activity of oils macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis. ( 30676066 )
2019
22
Invasive Candidiasis in Infants and Children: Recent Advances in Epidemiology, Diagnosis, and Treatment. ( 30678324 )
2019
23
Candidiasis: Red and White Manifestations in the Oral Cavity. ( 30693459 )
2019
24
Iron Chelator Deferasirox Reduces Candida albicans Invasion of Oral Epithelial Cells and Infection Levels in Murine Oropharyngeal Candidiasis. ( 30718249 )
2019
25
Efficacy of T-2307, a novel arylamidine, against ocular complications of disseminated candidiasis in mice. ( 30753506 )
2019
26
Multifocal muscle candidiasis of the legs in a patient with acute myeloid leukemia: A case report. ( 30813175 )
2019
27
Changing Epidemiology of Invasive Candidiasis in Children during a 10-Year Period. ( 30813283 )
2019
28
Therapeutic tools for oral candidiasis: Current and new antifungal drugs. ( 30818309 )
2019
29
Clinical value of (1,3)-β-D-glucan, mannan, antimannan IgG and IgM antibodies in diagnosis of invasive candidiasis. ( 30820536 )
2019
30
FTIR and Raman Spectroscopy-Based Biochemical Profiling Reflects Genomic Diversity of Clinical Candida Isolates That May Be Useful for Diagnosis and Targeted Therapy of Candidiasis. ( 30823514 )
2019
31
Acute and sub acute toxicity study and randomized clinical trial of polyherbal coded drug candicure in the management of acute vulvo-vaginal candidiasis. ( 30829209 )
2019
32
Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials. ( 30831231 )
2019
33
The Skin as a Window into Primary Immune Deficiency Diseases: Atopic Dermatitis and Chronic Mucocutaneous Candidiasis. ( 30832893 )
2019
34
Intravaginal Delivery of Syngonanthus nitens (Bong.) Ruhland Fraction Based on a Nanoemulsion System Applied to Vulvovaginal Candidiasis Treatment. ( 30890237 )
2019
35
Severe Cutaneous Candidiasis in a Liver Transplant Patient. ( 30891169 )
2019
36
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. ( 30893271 )
2019
37
Prevalence of Oral Candidiasis in Indian HIV Sero-Positive Patients with CD4+ Cell Count Correlation. ( 30906728 )
2019
38
Maternal pregnancy-induced hypertension increases the subsequent risk of neonatal candidiasis: A nationwide population-based cohort study. ( 30910150 )
2019
39
A Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis. ( 30910892 )
2019
40
ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. ( 30911804 )
2019
41
Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. ( 30925872 )
2019
42
Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis. ( 30930005 )
2019
43
Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation. ( 30945022 )
2019
44
Unusual case of intra-abdominal candidiasis following laparoscopic hysterectomy. ( 30948411 )
2019
45
Prophylactic regimens with fluconazole for candidiasis in neonates under 1.500g: A retrospective chart review of two cohorts. ( 30958318 )
2019
46
Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. ( 30968320 )
2019
47
Recurrent vulvo-vaginal candidiasis in Abidjan (Côte d'Ivoire): Aetiology and associated factors. ( 31010729 )
2019
48
Corrigendum to "Performance of Candida albicans germ tube antibodies (CAGTA) and its association with (1 → 3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC)" [Diagn Microbiol Infect Dis 2019;93(1):39-43]. ( 31027969 )
2019
49
Impact of Process Parameters on Particle Size Involved in Media Milling Technique Used for Preparing Clotrimazole Nanocrystals for the Management of Cutaneous Candidiasis. ( 31028492 )
2019
50
Reply to Vulvovaginal Candidiasis: Histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. ( 31029661 )
2019
Sources

Variations for Candidiasis

About this section
Sources

Expression for Candidiasis

About this section
Search GEO for disease gene expression data for Candidiasis.
Sources

Pathways for Candidiasis

About this section

Pathways related to Candidiasis according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.84 CARD9 CLEC7A DEFB4A HSP90AA1 HTN3 IFNG
2
Akt Signaling 65
Show member pathways
 13.35 HSP90AA1 IL10 IL17A IL17RA IL17RC IL1B
3
Cytokine Signaling in Immune system 67
Show member pathways
 13.27 HSP90AA1 IFNG IL10 IL17A IL17F IL17RA
4
Toll-like Receptor Signaling Pathway 1 38
Show member pathways
 13.05 CARD9 HSP90AA1 IFNG IL10 IL1B MBL2
5
Allograft rejection 38 1
Show member pathways
 12.83 HSP90AA1 IFNG IL10 IL17A IL1B STAT1
6
T cell receptor signaling pathway 38
Show member pathways
 12.49 IFNG IL10 IL17A IL1B
7
Immune response IL-23 signaling pathway 23
Show member pathways
 12.47 IFNG IL10 IL17A IL17F IL1B STAT1
8
NF-kappaB Signaling 4
12.42 CARD9 IFNG IL10 IL17A IL1B STAT1
9
Th17 cell differentiation 38
Show member pathways
 12.4 HSP90AA1 IFNG IL10 IL17A IL17F IL1B
10
Toxoplasmosis 38
Show member pathways
 12.21 IFNG IL10 IL1B STAT1
11
Necroptosis 38
Show member pathways
 12.17 HSP90AA1 IFNG IL1B STAT1
12
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.16 HSP90AA1 IFNG IL10 IL17A IL1B STAT1
13
Bacterial infections in CF airways 23
Show member pathways
 12.14 DEFB4A IFNG IL1B STAT1
14
C-type lectin receptor signaling pathway 38
Show member pathways
 12.13 CARD9 CLEC7A IL10 IL1B STAT1
15
Immune response IFN gamma signaling pathway 23
Show member pathways
 12.01 IFNG IL10 IL17A IL17RC IL1B STAT1
16
Tuberculosis 38
11.99 CARD9 CLEC7A IFNG IL10 IL1B STAT1
17
IL12-mediated signaling events 1
Show member pathways
 11.89 IFNG IL1B STAT1
18
Amoebiasis 38
11.81 IFNG IL10 IL1B
19
Rheumatoid arthritis 38
11.79 IFNG IL17A IL1B
20
Innate Lymphoid Cell Differentiation Pathways 66
11.76 IFNG IL10 IL17A IL1B
21
Th1 Differentiation Pathway 66
Show member pathways
 11.75 IFNG IL10 IL17A IL17F IL1B STAT1
22
Glucocorticoid receptor regulatory network 1
11.73 HSP90AA1 IFNG STAT1
23
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.73 IL17A IL17F IL17RA IL17RC TRAF3IP2
24
Dendritic Cells Developmental Lineage Pathway 66
11.72 IFNG IL10 IL17RA IL1B
25
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.69 IFNG IL10 IL17A IL1B
26
IL-17 Family Signaling Pathways 66
Show member pathways
 11.61 DEFB4A HSP90AA1 IFNG IL17A IL17F IL17RA
27
Malaria 38
11.49 IFNG IL10 IL1B
28
Interleukin-4 and 13 signaling 67
11.49 HSP90AA1 IL10 IL17A IL17F IL1B STAT1
29
Aryl Hydrocarbon Receptor Pathway 1
11.47 HSP90AA1 IFNG IL1B
30
Nucleotide-binding Oligomerization Domain (NOD) pathway 1
11.39 CARD9 HSP90AA1 IL1B
31
Type II interferon signaling (IFNG) 1
11.34 IFNG IL1B STAT1
32
African trypanosomiasis 38
11.34 IFNG IL10 IL1B
33
Development and heterogeneity of the ILC family 1
11.27 IFNG IL17A IL1B
34
Cytokines and Inflammatory Response 1
11.21 IFNG IL10 IL1B
Sources

GO Terms for Candidiasis

About this section

Cellular components related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 APCS DEFB4A IFNG IL10 IL17A IL17F
2 extracellular region GO:0005576 9.36 APCS DEFB4A HSP90AA1 HTN3 IFNG IL10

Biological processes related to Candidiasis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 IFNG IL10 IL17A IL17F IL1B
2 inflammatory response GO:0006954 9.93 CLEC7A IL10 IL17A IL17F IL1B
3 immune response GO:0006955 9.91 AIRE DEFB4A IFNG IL10 IL17A IL1B
4 defense response to bacterium GO:0042742 9.88 DEFB4A HTN3 IL10 MBL2
5 cytokine-mediated signaling pathway GO:0019221 9.85 HSP90AA1 IL10 IL17A IL17F IL1B STAT1
6 response to drug GO:0042493 9.8 CARD9 IL10 STAT1
7 defense response to Gram-positive bacterium GO:0050830 9.77 CARD9 DEFB4A MBL2
8 humoral immune response GO:0006959 9.73 AIRE IFNG TRAF3IP2
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.69 HSP90AA1 IFNG IL1B
10 chaperone-mediated protein complex assembly GO:0051131 9.62 APCS HSP90AA1
11 defense response to fungus GO:0050832 9.62 HTN3 IL17A IL17RA IL17RC
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IFNG IL1B
13 negative regulation of growth of symbiont in host GO:0044130 9.61 IL10 MBL2
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 IL10 IL1B
15 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.58 IFNG STAT1
16 negative regulation of viral process GO:0048525 9.55 APCS MBL2
17 granulocyte chemotaxis GO:0071621 9.52 IL17RA IL17RC
18 fibroblast activation GO:0072537 9.49 IL17A IL17RA
19 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IFNG IL1B
20 regulation of interleukin-6 biosynthetic process GO:0045408 9.46 CARD9 IL17F
21 positive regulation of interleukin-6 secretion GO:2000778 9.46 IL17A IL17F IL17RC IL1B
22 positive regulation of interleukin-23 production GO:0032747 9.43 IFNG IL17A IL17RA
23 regulation of interleukin-2 biosynthetic process GO:0045076 9.4 CARD9 IL17F
24 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.26 IL17A IL17F IL17RA IL17RC
25 interleukin-17-mediated signaling pathway GO:0097400 8.92 IL17A IL17F IL17RA IL17RC

Molecular functions related to Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IFNG IL10 IL17A IL17F IL1B
2 interleukin-17 receptor activity GO:0030368 8.96 IL17RA IL17RC
Sources

Sources for Candidiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....